Sponsor

Daiichi Sankyo

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Daiichi Sankyo appears in 208 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials208
Recruiting shown11
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941 · lead sponsor · 2026-09-17
RECRUITING
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341 · lead sponsor · 2025-12-03
RECRUITING
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate CancerNCT07189403 · lead sponsor · 2025-11-04
RECRUITING
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · lead sponsor · 2025-10-24
RECRUITING
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)NCT06809764 · lead sponsor · 2025-02-21
RECRUITING
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)NCT06362252 · lead sponsor · 2024-07-22
RECRUITING
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06203210 · lead sponsor · 2024-05-21
RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)NCT06330064 · lead sponsor · 2024-04-10
RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · lead sponsor · 2024-02-26
RECRUITING
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)NCT06210776 · lead sponsor · 2024-01-15
RECRUITING
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · lead sponsor · 2023-12-30
RECRUITING
A Study of DS-3939a in Participants With Solid TumorsNCT07739966 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754 · lead sponsor · 2026-09-04
NOT_YET_RECRUITING
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerNCT07092254 · lead sponsor · 2025-09-01
ACTIVE_NOT_RECRUITING
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6iNCT06975371 · lead sponsor · 2025-04-14
COMPLETED
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab DeruxtecanNCT06833268 · lead sponsor · 2025-01-20
COMPLETED
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsNCT06644768 · lead sponsor · 2024-10-30
ACTIVE_NOT_RECRUITING
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line TreatmentsNCT06617390 · lead sponsor · 2024-08-15
COMPLETED
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerNCT06686602 · lead sponsor · 2024-07-09
COMPLETED
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of TreatmentNCT06557967 · lead sponsor · 2024-03-01
COMPLETED
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast CancerNCT06040593 · lead sponsor · 2023-07-31
COMPLETED
A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast CancerNCT05769751 · lead sponsor · 2023-03-15
COMPLETED
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · lead sponsor · 2023-01-11
ACTIVE_NOT_RECRUITING
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung CancerNCT05769764 · lead sponsor · 2022-12-19
COMPLETED
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab DeruxtecanNCT05458401 · lead sponsor · 2022-11-11
COMPLETED
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseNCT05400369 · lead sponsor · 2022-08-10
COMPLETED
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · lead sponsor · 2022-07-08
ACTIVE_NOT_RECRUITING
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NCT05280470 · lead sponsor · 2022-03-09
ACTIVE_NOT_RECRUITING
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340 · lead sponsor · 2022-03-04
ACTIVE_NOT_RECRUITING
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerNCT04676477 · lead sponsor · 2021-06-11
ACTIVE_NOT_RECRUITING
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)NCT04484142 · lead sponsor · 2021-03-30
COMPLETED
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)NCT04644237 · lead sponsor · 2021-03-19
COMPLETED
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerNCT04619004 · lead sponsor · 2021-02-02
ACTIVE_NOT_RECRUITING
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)NCT04656652 · lead sponsor · 2020-12-21
ACTIVE_NOT_RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · lead sponsor · 2020-12-04
ACTIVE_NOT_RECRUITING
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)NCT04526691 · lead sponsor · 2020-09-15
ACTIVE_NOT_RECRUITING
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerNCT04042701 · lead sponsor · 2020-02-10
ACTIVE_NOT_RECRUITING
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerNCT03255083 · lead sponsor · 2019-04-10
TERMINATED
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]NCT03734029 · lead sponsor · 2018-12-27
COMPLETED
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]NCT03529110 · lead sponsor · 2018-08-09
COMPLETED
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerNCT03523572 · lead sponsor · 2018-08-02
COMPLETED
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]NCT03523585 · lead sponsor · 2018-08-01
COMPLETED
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerNCT03505710 · lead sponsor · 2018-05-21
TERMINATED
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerNCT03260491 · lead sponsor · 2017-10-30
ACTIVE_NOT_RECRUITING
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)NCT03248492 · lead sponsor · 2017-08-25
TERMINATED
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)NCT02673866 · lead sponsor · 2016-02-01
WITHDRAWN
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 DiabetesNCT05107063 · lead sponsor · 2016-01-20
COMPLETED
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on MetforminNCT02647320 · lead sponsor · 2016-01-01
COMPLETED
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersNCT04019652 · lead sponsor · 2015-11-19
COMPLETED
Cancer Venous Thromboembolism (VTE)NCT02073682 · lead sponsor · 2015-07-16
COMPLETED
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsNCT02452424 · lead sponsor · 2015-07-02
TERMINATED
A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal ImpairmentNCT02448628 · lead sponsor · 2015-05-01
COMPLETED
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaNCT02345057 · lead sponsor · 2015-01-01
COMPLETED
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsNCT02345044 · lead sponsor · 2015-01-01
COMPLETED
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)NCT02134015 · lead sponsor · 2014-03-01
TERMINATED
AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) TreatmentNCT01973569 · lead sponsor · 2013-10-01
COMPLETED
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes MellitusNCT02004678 · lead sponsor · 2013-09-01
COMPLETED
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose StudyNCT01956305 · lead sponsor · 2013-09-01
COMPLETED
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)NCT01499043 · lead sponsor · 2012-05-25
TERMINATED
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or LymphomasNCT01588678 · lead sponsor · 2012-04-01
COMPLETED

Drugs studied in this sponsor's trials

78 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Daiichi Sankyo as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo26
trastuzumab deruxtecan24
carboplatin19
paclitaxel14
olmesartan medoxomil13
datopotamab deruxtecan11
pembrolizumab11
capecitabine10
placebo RxCUI 8375 · Lead sponsor in 21 linked trial(s) · 0 currently recruiting 26 trials trastuzumab deruxtecan RxCUI 2267582 · Lead sponsor in 10 linked trial(s) · 8 currently recruiting 24 trials carboplatin RxCUI 40048 · Lead sponsor in 6 linked trial(s) · 9 currently recruiting 19 trials paclitaxel RxCUI 56946 · Lead sponsor in 4 linked trial(s) · 6 currently recruiting 14 trials olmesartan medoxomil RxCUI 118463 · Lead sponsor in 13 linked trial(s) · 0 currently recruiting 13 trials datopotamab deruxtecan RxCUI 2703033 · Lead sponsor in 4 linked trial(s) · 4 currently recruiting 11 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 6 linked trial(s) · 3 currently recruiting 11 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 3 currently recruiting 10 trials colesevelam hydrochloride RxCUI 141625 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 10 trials pemetrexed RxCUI 68446 · Lead sponsor in 3 linked trial(s) · 5 currently recruiting 9 trials cisplatin RxCUI 2555 · Lead sponsor in 2 linked trial(s) · 3 currently recruiting 7 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 3 currently recruiting 6 trials amlodipine RxCUI 17767 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 4 currently recruiting 5 trials durvalumab RxCUI 1919503 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting 5 trials trastuzumab RxCUI 224905 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 5 trials colesevelam RxCUI 141626 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials erlotinib RxCUI 337525 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials losartan potassium RxCUI 203160 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials osimertinib RxCUI 1721560 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting 4 trials pioglitazone RxCUI 33738 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 3 currently recruiting 3 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials eribulin RxCUI 1045453 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 3 trials

Sponsor roles

lead sponsor118
collaborator90
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.